

## Press Release

---

# Nicox : Termination of the liquidity contract with Kepler Cheuvreux

---

January 3, 2024 – release at 7:30 am CET  
Sophia Antipolis, France

**Nicox SA** (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the termination of the liquidity contract dated August 3<sup>rd</sup>, 2020 entered into with Kepler Cheuvreux (the “Contract”). Such termination is effective as of January 1<sup>st</sup>, 2024.

When the Contract was implemented, the following resources appeared on the liquidity account:

- 0 shares
- € 500, 000 in cash

On the termination date of the Contract, the following resources appeared on the liquidity account and will be returned:

- 311 067 shares
- € 7,864.53 in cash

## Nicox Corporate Status Update

The Company is currently funded until the end of June 2024, exclusively on the basis of the development of NCX 470. The Company is pursuing licensing discussions which could extend the cash runway. In parallel, the Company is exploring multiple strategic options and is also discussing with its creditors to restructure its debt.

### About Nicox

---

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIA® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.

For more information [www.nicox.com](http://www.nicox.com).

### Analyst coverage

---

Bryan, Garnier & Co  
H.C. Wainwright & Co

Eric Yoo  
Yi Chen

Paris, France  
New York, U.S.



*The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.*

### Contacts

---

Nicox

Gavin Spencer  
Executive Vice President, Chief Business Officer  
& Head of Corporate Development  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

### Forward-Looking Statements

---

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in section 2.7 of the "*Rapport Annuel 2022*" and in section 4 of the "*Rapport semestriel financier et d'activité 2023*" which are available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

#### **Nicox S.A.**

Drakkar 2  
Bât D, 2405 route des Dolines  
06560 Valbonne, France  
T +33 (0)4 97 24 53 00  
F +33 (0)4 97 24 53 99